Volume : 10, Issue : 02, February – 2023
Title:
13.TO FORMULATION AND IN-VITRO EVALUATION OF LIPOSOMAL DRUG DELIVERY SYSTEM OF DECITABINE
Authors :
Bandhipotu Geethanjali, Zeenath Ruhy
Abstract :
The medicine launch from Liposomes depends upon many aspects consisting of the structure of Liposomes, the kind of medicine encapsulated and nature of the cell. Once it is released a medicine that generally goes across the membrane of a cell will certainly enter the cell, various other medicines will not go into. Decitabine is a short biological half-life. This research study targeted at Formula As well as In-Vitro Assessment Of Liposomal Drug Shipment System Of Decitabine in order to boost its bioavailability. In examination study the result of the differing make-up of lipids on the residential or commercial properties such as encapsulation efficiency, fragment size as well as medication release were researched. Stage change research was executed to validate the total interaction of Decitabine with bilayer structure of liposome. Moreover, the launch of the drug was likewise modified as well as crossed a duration of 8 h in all solutions. F1 became one of the most acceptable formula in so far as its residential or commercial properties were concerned. Additionally, release of the medicine from the most sufficient formula (F1) was assessed via dialysis membrane layer to get the idea of medication launch.
Keywords: Liposomes, Decitabine, Bioavailability.
Cite This Article:
Please cite this article in press Bandhipotu Geethanjali et al, To Formulation And In-Vitro Evaluation Of Liposomal Drug Delivery System Of Decitabine., Indo Am. J. P. Sci, 2023; 10 (02).
Number of Downloads : 10
References:
2. Yang D, Ge L. Preparation characterization and pharmacokinetics of sterically stabilized Nimodipine containing liposomes. Drug Development and Industrial Pharmacy 2006; 32:219.
3. Kim A, Lee EH, Choi SH, Kim CK. In vitro and in vivo transfection efficiency of a novel ultradeformable cationic liposome. Biomaterials 2004, 25, 305–313.
4. Han HD, Jeon YW, Kwon HJ, Jeon HN, Byeon Y, Lee CO, Cho SH and Shin BC: Therapeutic efficacy of doxorubicin delivery by a CO2 generating liposomal platform in breast carcinoma. Acta Biomater 2015; 24: 279-285.
5. Kan P, Tsao CW and Wang AJ: A liposomal formulation able to incorporate a high content of paclitaxel and exert promising anticancer effect. J Drug Deliv 2011; 1-9.
6. Akbarzadeh A, Rezaei-Sadabady R. Liposome, classification preparation and applications, Nanoscale Research Letters 2013; 8(1):102.
7. Kantarjian H, Issa JP, Rosenfeld CS, et al. “Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study”. Cancer 2006; 106 (8): 1794–1803
8. Kantarjian HM, O’Brien S, Cortes J, et al. “Results of decitabine (5-aza-2’deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003; 98 (3): 522–528
9. Dunn J, Thabet S, Jo H. Flow-Dependent epigenetic DNA methylation in endothelial gene expression and atherosclerosis. Arterioscler Thromb Vasc Biol 2015; 35 (7): 1562–9.